克隆氏症:KOL Insight

Crohn's Disease - KOL Insight

出版日期: 2022年09月09日 | 出版商:

FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格

簡介目錄

AbbVie的Skyrizi的有效性高，不過，限制其使用與治療流程發展的課題是什麼？在口服sufingoshinmojureta的領域，專家怎麼評價與BMS的Zeposia和Pfizer的etrasimod競爭的優點，怎樣的要素對處方帶來影響？

本報告提供克隆氏症市場調查，市售的治療藥和開發平台預測評價。授權用戶，可閱覽報告全文，以及附件區域的Report Highlights slidedeck和以下的KOL Bulletins。

成藥
- TNF抑制劑(Remicade，Humira，Cimzia)
- entibio(vedolizumab; Takeda)
- Stelara(ustekinumab; Johnson & Johnson)
- Tysabri(natalizumab; Biogen)
- sukiriji(risankizumab; AbbVie)
開發平台醫藥品
- Tremfya (guselkumab; Janssen Biotech)
- Mirikizumab (Eli Lilly)
- Brazikumab (AstraZeneca)
- Rinvoq (upadacitinib; AbbVie)
- Jyseleca (filgotinib; Galapagos/Gilead Sciences)
- Zeposia (ozanimod; Bristol Myers Squibb)
- Etrasimod (Pfizer)

今後的治療趨勢

重要的洞察的彙整
- 克隆氏症的未來治療策略，有轉移到JAK抑制劑，p19s第1或第2線的可能性

附錄

關於KOL
- 北美的KOLs
- 歐洲的KOLs

簡介目錄

KOLs are impressed with the efficacy of AbbVie's Skyrizi but what challenges do they identify that could limit its use and progress in the treatment algorithm? In the oral sphingosine modulator sector, how do experts assess the competing merits of BMS' Zeposia and Pfizer's etrasimod and what factors will influence prescribing? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.

Executive Summary (1)

Future treatment algorithm

Research objectives (303)

Marketed drugs (178)
- TNF inhibitors (Remicade, Humira, Cimzia) (55)
- Entyvio (vedolizumab; Takeda) (43)
- Stelara (ustekinumab; Johnson & Johnson) (39)
- Tysabri (natalizumab; Biogen) (14)
- Skyrizi (risankizumab; AbbVie) (27)

Pipeline drugs (124)
- Tremfya (guselkumab; Janssen Biotech) (19)
- Mirikizumab (Eli Lilly) (16)
- Brazikumab (AstraZeneca) (13)
- Rinvoq (upadacitinib; AbbVie) (38)
- Jyseleca (filgotinib; Galapagos/Gilead Sciences) (16)
- Zeposia (ozanimod; Bristol Myers Squibb) (18)
- Etrasimod (Pfizer) (4)